OR WAIT null SECS
June 04, 2024
The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.
June 03, 2024
The Netherlands plant is expected to provide solutions that can help further the development of advanced therapies.
May 31, 2024
Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.
May 24, 2024
With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.
May 23, 2024
The CDMO will run the active pharmaceutical ingredient pilot plant in Sandwich, UK, along with development laboratories.
May 21, 2024
The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.
May 20, 2024
The facility, company says, will be its first that covers end-to-end ADC production.
May 16, 2024
The CDMO’s latest business venture reaffirms its commitment to the development of novel radiopharmaceuticals.
May 15, 2024
The company has financially committed more than $3.8 billion since the COVID-19 pandemic into keeping the medication and vaccine production process in France.
May 14, 2024
The development project adds an additional 157,500 square feet to the existing facility in the process.